Argentina vs Belarus: Average cost of drugs for extensively drug-resistant tuberculosis
Argentina
4,721 constant 2022 US$
in 2024
Belarus
4,600 constant 2022 US$
in 2023
Argentina rank
12th
Belarus rank
13th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Argentina
- Belarus
How they compare
Argentina currently reports 4,721 constant 2022 US$ against 4,600 constant 2022 US$ in Belarus, a difference of 121 constant 2022 US$.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Argentina ahead.
Argentina ranks 12th and Belarus ranks 13th of 56 countries.
Across the 2 decades both report, Argentina averaged higher in 1 and Belarus in 1.
Head to head by decade
| Decade | Argentina | Belarus | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,142 constant 2022 US$ | 7,617 constant 2022 US$ | 1,525 constant 2022 US$ | Argentina |
| 2020s | 1,907 constant 2022 US$ | 5,867 constant 2022 US$ | 3,960 constant 2022 US$ | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Argentina or Belarus?
- Argentina, at 4,721 constant 2022 US$ against 4,600 constant 2022 US$ in Belarus as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Argentina and Belarus?
- 121 constant 2022 US$, with Argentina ahead.
- How many years of comparable data are there for Argentina and Belarus?
- 6 years are reported by both, from 2017 to 2023.
- How do Argentina and Belarus rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Argentina ranks 12th and Belarus ranks 13th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.